Compare KNDI & BDSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KNDI | BDSX |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 62.5M |
| IPO Year | N/A | 2020 |
| Metric | KNDI | BDSX |
|---|---|---|
| Price | $0.79 | $6.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | ★ 254.5K | 69.7K |
| Earning Date | 03-13-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $104,035,613.00 | $80,173,000.00 |
| Revenue This Year | N/A | $20.75 |
| Revenue Next Year | N/A | $25.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 22.29 |
| 52 Week Low | $0.78 | $3.44 |
| 52 Week High | $1.81 | $31.20 |
| Indicator | KNDI | BDSX |
|---|---|---|
| Relative Strength Index (RSI) | 31.09 | 42.52 |
| Support Level | $0.79 | $6.55 |
| Resistance Level | $0.88 | $7.03 |
| Average True Range (ATR) | 0.09 | 0.52 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 1.39 | 25.79 |
Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Covid tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.